Introduction
Sinonasal undifferentiated carcinoma (SNUC) is a rare aggressive malignancy of the sinonasal tract first described by Frierson et al in 1986 . SNUC patients typically present with large, locally invasive lesions that often destruct the orbital and/or cranial bones [1] . A multimodal therapy including chemoradiation and surgery offers the best treatment results. However, the outcome remains poor, with the overall 5-year survival ranging between 22% and 42% [2, 3] . Here, we performed a comprehensive genomic profiling of a cohort of SNUCs and a morphological spectrum of high-grade/poorly-differentiated sinonasal carcinomas aiming (1) to identify potential novel molecular therapeutic targets, and (2) to explore IDH2 R172 mutations in sinonasal carcinomas 401 Figure 1 . Frequencies of IDH1 and IDH2 mutations in sinonasal carcinomas and olfactory neuroblastoma. SNUC = sinonasal undifferentiated carcinoma; PDCA-GL = poorly differentiated non-intestinal-type adenocarcinoma/poorly-differentiated carcinoma with focal glandular differentiation; HGNEC = high-grade neuroendocrine carcinoma, large cell type; SCNEC = small cell neuroendocrine carcinoma; SMARCB1-def = SMARCB1-deficient sinonasal carcinoma; NMC = NUT midline carcinoma; MD-ITAC = moderately-differentiated intestinal-type adenocarcinoma with signet-ring cells and mucinous features; PDCA-NE-GL = poorly-differentiated carcinoma with neuroendocrine and glandular differentiation; ONB = olfactory neuroblastoma.
carcinomas with or without neuroendocrine or glandular differentiation. Twenty-two cases were retrieved. Six additional cases prospectively sequenced as clinical samples between January 2014 and February 2017 were added to the study. An additional 19 cases were received from three collaborating institutions after obtaining their respective IRB approvals. Details on pathology slides' review and results of ancillary studies are provided in the supplementary material, Supplementary materials and methods and Table S1 . Cohort 1 (N = 30, including matched metastasis in two cases) was profiled by MSK-IMPACT TM (MSK-Integrated Mutation Profiling of Actionable Cancer Targets). Cohort 2 (N = 17) was examined for the presence of IDH1/2 exon 4 mutations by Sanger sequencing. The diagnostic spectrum of the tumour categories studied is shown in Figure 1 .
Immunohistochemistry and chromogenic in situ hybridization (CISH)
Immunohistochemistry and CISH were performed according to the manufacturer's recommendations (Ventana Medical Systems, Tucson, AZ, USA) (supplementary material, Supplementary materials and methods) using the antibodies and CISH probes listed in Table S2 of the supplementary material.
DNA extraction and hybridization exon-capture next-generation sequencing
Tumours were profiled for genomic alterations in 279 or 410 key cancer-associated genes in 13 and 17 cases, respectively, using our clinically-validated custom deep sequencing MSK-IMPACT TM assay [4] . Twenty samples with matched normal DNA were selected for allele-specific copy number and cancer cell fraction (CCF) analysis by FACETS [5] , rendering successful results in 19 samples (supplementary material, Supplementary materials and methods).
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Statistical analysis
Statistical analyses were performed using SPSS software 22.0 (IBM Corporation, New York, NY, USA). P values less than 0.05 were considered significant.
Results and discussion
Clinical features
Sinonasal carcinomas occurred in 29 men (61.7%) who were significantly younger than women, presenting at the median age of 50 (range 33-95 years) and 72 (range 33-83 years), respectively (p = 0.0006, two-tailed Student's t-test) (supplementary material, Table S1 ). Most (83.3%) cases were detected as multi-compartmental masses rendering the majority (86.7%) of patients to present at clinical stage IV. Multimodal treatment was administered in 83.3% cases and included surgery with radiation and/or chemotherapy ( Table 1) .
Genomic profile by MSK-IMPACT TM
Most notably, IDH2 R172 mutations were detected in 12 (40%) carcinomas of various histological types, and SMARCB1 deletions were detected in four (13.3%) cases. Frequent alterations involved tumour suppressor genes including TP53 (33.3%), CDKN2A/CDKN2B (16.7%), RB1 (10%), and TSC1 (10%). Loss of heterozygosity (LOH) was detected in four of five TP53-mutated cases and in two of three TSC1-mutated carcinomas (Figure 2A ). Aside from IDH2 and SMARCB1, recurrent alterations were detected in other epigenetically important genes including CREBBP (13.3%) and SETD2 (10%), and in the oncogenes MYC (16.7%) and KRAS (10%), including the KRAS G12D variant in one SNUC (Figure 2A ). Copy number analysis revealed frequent gains involving chromosomes 8 and 20 and chromosome arms 1q and 17q; recurrent losses were detected in 3p and in chromosomes 13, 14, 15, 16, and 18 . Notably, the majority of SNUCs showed 8q gain (71.4%) and 3p loss (57.1%) ( Figure 2B ).
IDH2-mutated sinonasal carcinomas
Activating hotspot IDH1/IDH2 mutations have been identified in various cancers. IDH1 mutations are predominant in solid tumours: gliomas [6] , chondrosarcomas [7] , and intrahepatic cholangiocarcinoma [8] . IDH2 mutations are more frequent in acute myeloid leukaemia (AML) [9] and angioimmunoblastic T-cell lymphoma [10] . Isocitrate dehydrogenase 1 (IDH1) and IDH2 are homodimeric enzymes that catalyse the conversion of isocitrate to α-ketoglutarate. The mutant protein, IDH1 or IDH2, loses its normal enzymatic activity and acquires a gain-of-function neomorphic enzymatic activity leading to abnormally increased levels of the 'oncometabolite' (R)-2-hydroxyglutarate [9] . In all except one low tumour purity sample, the CCF with IDH2 R172 mutation was high (average 0.87, range 0.4-1.0) (supplementary material, Table S4 ). In the case with matched metastasis, the CCF indicated the presence of IDH2 variant in (nearly) all cancer cells at both sites, suggesting that they are likely clonal ( Figure 3 ). Among 12 IDH2-mutated cases, co-existing recurrent alterations were detected in TP53 (41.7%), CDKN2A/2B (33.3%), MYC (33.3%), SETD2 (25%), and SPEN (16.7%).
Three (25%) cases harboured a second, non-hotspot IDH2 mutation. AKT1 E17K and KIT D816V hotspot variants were each detected in one case. IDH1/2 pathogenic mutations were often found to co-exist with mutations affecting other oncogenic pathways. Studies on IDH1/2-mutated gliomas give a notion that the glial cells may become susceptible to mutant IDH1 through activation of MAPK, PI3K/Akt, and MYC, and loss of p53 signalling [11] . We hypothesize that the concurrent genetic alterations in IDH2-mutated sinonasal carcinomas may collaborate with mutant IDH2 to induce and promote carcinogenesis in these tumours.
The high frequency of IDH2 mutations in cohort 1 prompted testing of an extended set of sinonasal tumours for the presence of IDH1/2 hotspot mutations by Sanger sequencing (cohort 2, N = 17). The frequencies and distribution of IDH2 mutations in both cohorts (N = 47) are provided in Figure 1 . IDH2 R172S (58.8%), R172T (23.5%), R172M (11.8%), and R172G (5.9%) were found in 12 (70.6%) men (median age 49, range 39-85 years) and five (29.4%) women (median age 62, range 49-83 years) (supplementary material, Table  S1 ). In a recent study of 11 SNUCs, Jo et al found IDH2 R172 mutations in 55% cases [12] . In addition to the higher IDH2 mutation detection rate in SNUC, the results of our larger, histologically diverse cohort show (1) that IDH2 mutations can also be found in poorly-differentiated sinonasal carcinomas other than SNUC; (2) that they are likely clonal (in most cases); and (3) that they frequently co-exist with MYC amplifications.
Clinical trials with established targeted therapies against IDH2 mutant proteins are in progress. Preliminary findings of an ongoing phase 1 clinical trial have shown that the mutant IDH2-inhibitor AG-221 produces clinical responses in about 40% of patients with AML and myelodysplastic syndrome [13] . These results may provide a rationale for taking a similar approach in the treatment of IDH2-mutated sinonasal carcinomas.
Morphologically, except for one poorly-differentiated non-intestinal-type adenocarcinoma, all IDH2-mutated tumours were arranged in sheets or lobules. Irrespective of the final diagnosis, they shared very similar cytological features and consisted of large undifferentiated epithelial tumour cells in most cases (Figure 3 and supplementary material, Figure S1 ). However, they were not notably morphologically distinct from their IDH2-wild-type histological counterparts (supplementary material, Figure S2 ). Functional studies on different cell lines including murine bone marrow cells, [5] . Genome-wide copy number alterations are colour-coded according to the legend and summarized at the cohort level and by tumour type. SNUC = sinonasal undifferentiated carcinoma; PDCA-GL = poorly differentiated non-intestinal-type adenocarcinoma/poorly-differentiated carcinoma with focal glandular/acinar differentiation; HGNEC = high-grade neuroendocrine carcinoma, large cell type; SCNEC = small cell neuroendocrine carcinoma; SMARCB1-def = SMARCB1-deficient sinonasal carcinoma; NMC = NUT midline carcinoma; MD-ITAC = moderately-differentiated intestinal-type adenocarcinoma; PDCA-NE-GL = poorly-differentiated carcinoma with neuroendocrine and glandular differentiation; LOH = loss of heterozygosity.
adipocytes, and astrocytes showed that increased intracellular (R)-2-hydroxyglutarate led to hypermethylation of target genes and the subsequent block in cellular differentiation [14] [15] [16] . IDH2 mutations in sinonasal carcinomas may have similar consequences, leading to a block in cellular differentiation and resulting in either undifferentiated or poorly-differentiated carcinomas in this location.
The outcome in respect to the IDH2 mutation status is provided in Table 1 . Although IDH2-mutated sinonasal IDH2 R172 mutations in sinonasal carcinomas 407 carcinomas were associated with a trend of improved disease-free survival and overall survival, such a trend did not reach a statistically significance level (log rank test, p = 0.112 and p = 0.145, respectively) (supplementary material, Figure S3 ).
SMARCB1-deficient sinonasal carcinomas
SMARCB1 deletions detected in cohort 1 occurred in four men (age range 47-95 years) ( Table 1) . SMARCB1-deficient sinonasal carcinomas displayed a relative paucity of co-existing mutations, emphasizing the oncogenic role of SMARCB1 loss in these tumours (Figure 2 and supplementary material, Table S5 ).
Small cell neuroendocrine carcinoma (SCNEC) of the sinonasal tract
In one SCNEC, ERBB3 V104L co-existed with TP53 mutations and BCL2 and MYC amplifications. In another, along with TP53 and CREBBP mutations, there were two pathogenic RB1 mutations and one likely loss-of-function INPP4B mutation ( Figure 2 and supplementary material, Figure S4 ). Mutations of TP53 and RB1, up-regulation of BCL2 signalling, and activation of the MYC and PI3K pathways are frequent in pulmonary small cell carcinomas [17] . A notable similarity in the mutational profiles of sinonasal SCNEC and its lung counterpart supports their common genetic background. Novel findings, ERBB3 V104L oncogenic mutation [18] , and INPP4B loss-of-function mutation may represent alternative mechanisms of PI3K/Akt pathway activation [19] in sinonasal SCNECs.
In conclusion, given the established knowledge on the biological significance of IDH1/2 mutations in other cancer types, our results suggest the IDH2 R172 mutations may play an important role in the carcinogenesis of SNUC. IDH2-mutated sinonasal carcinomas may be amenable to IDH2-targeted therapy. Table S1 . Initially rendered diagnoses and revised (final) diagnoses with ancillary studies results (cohort 1: cases 1-30, and cohort 2: cases 31-47) Table S2 . Antibodies used for immunohistochemical studies and in situ hybridization probes Table S3 . PCR and sequencing primers for exon 4 of IDH1 and IDH2 Table S4 . Mutational profile with clonal heterogeneity assessment and loss of heterozygosity status in sinonasal carcinomas (cohort 1) Table S5 . Genetic alterations with variant frequencies in sinonasal carcinomas detected by MSK-IMPACT TM in sinonasal carcinomas (cohort 1) Table S6 . FACETS analysis: significant copy number variations at the gene level Table S7 . FACETS analysis: significant copy number variations at the chromosome arm level
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